[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aneurysm-aortic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aneurysm-aortic":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,70,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100614678","fibroblast-line-evaluation-for-col5a-expression-and-thoracic-aortic-aneurysms-in-vitro-characterization-of-cutaneous-fibroblasts-in-adult-patients-100614678",false,"NCT07282717","Fibroblast Line Evaluation for COL5A eXpression and Thoracic Aortic Aneurysms: in Vitro Characterization of Cutaneous Fibroblasts in Adult Patients","FLEX5 project","Inclusion Criteria:\n\n* Subjects aged 18 and above\n* Mutation in COL5A\n* Signed informed consent\n\nExclusion Criteria:\n\n* Corticosteroid or Steroids or Fluorochinolones treatment within six months before enrollment\n* Subjects on chronic immunosuppressive therapies such as oral steroids, but also on chronic topical steroids in the area of investigation\n* Subject on anticoagulant therapy\n* History of coagulation factor defects\u002Falterations (data found in anamnesis and medical records)\n* A history of keloid formation (data found in anamnesis and medical records)\n* Anesthetic drug allergy (data found in anamnesis and medical records)","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","OBSERVATIONAL","This study examines adults with COL5A gene mutations to understand why some develop aortic aneurysms while others do not. Participants provide a small skin biopsy, and researchers analyze fibroblasts to evaluate collagen production, extracellular matrix organization, and connective-tissue signaling pathways. The goal is to identify biological differences that may explain variable vascular risk and support future personalized monitoring and treatment strategies.",[24,25],"Mutations Affecting the COL5A Gene","Aneurysm Aortic",[27,28,29,30],"COL5A","FIBROBLASTS","ascending and descending aortic aneurysms","thoracic aortic aneurysms","RECRUITING","2026-07-01",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2026-06-24",{"date":39,"type":20},"2028-12",{"name":41,"class":42},"IRCCS Policlinico S. Donato","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100626894","evaluation-of-the-efficacy-of-ischemic-preconditioning-to-protect-against-acute-kidney-injury-after-open-surgery-for-juxtarenal-abdominal-aortic-aneurysm-100626894","NCT07441564","Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Juxtarenal Abdominal Aortic Aneurysm","EPAKI","Inclusion Criteria:\n\n* Patients aged 18-85 years\n* Patients with juxtarenal abdominal aortic aneurysms scheduled for open surgery\n* Patients with juxtarenal abdominal aortic aneurysms, which require suprarenal aortic cross clamping\n* Patients with juxtarenal abdominal aortic aneurysms, which are of atheromatous etiology or which developed after aortic dissection\n* Affiliation with, or beneficiary of a Social security (national health insurance) scheme\n* Adult having read and understood the information letter and signed the consent form\n* Women of childbearing potential with effective contraception according WHO definition (estrogen-progestin contraception or intrauterine device or male condom) since at least 1 month with a negative blood pregnancy test by b-HCG at inclusion.\n* Women surgically sterile (absence of ovaries and\u002For uterus or tubal ligation)\n* Postmenopausal women: confirmation of non-medically induced amenorrhea since at least 12 months prior to the inclusion visit\n\nExclusion Criteria:\n\n* Patients dependent from dialysis\n* Patients with aortic aneurysms, which require reconstruction of the visceral arteries\n* Patients with aortic aneurysms, which require supra-visceral aortic cross clamping\n* Patients with wall thrombus or calcification of inter- and suprarenal aorta\n* Patients with septic aortitis\n* Patients with aneurysm requiring stent graft (EVAR) explantation\n* Patients requiring emergency surgery\n* Patients receiving treatments that may interact with preconditioning: Nicorandil and Glibenclamide\n* Pregnant or parturient or breastfeeding woman or absence of proven contraception\n* Person deprived of liberty by an administrative or judiciary decision or person placed under judicial protection, under guardianship or curatorship\n* Person participating to another trial during the month before randomization\n* Medical history or psychological or sensorial abnormality prone to inhibit the subject to understand the conditions required for his\u002Fher participation to the protocol or unable to give an informed consent","85 Years",{"count":53,"type":20},206,"INTERVENTIONAL",[56],"NA","Juxta-renal abdominal aortic aneurysms (AAA) are challenging to treat with standard endovascular techniques (EVAR) due to their proximity to the renal arteries. Open surgical repair continues to be used in patients unsuitable for EVAR but carries a high risk of acute kidney injury (AKI), up to 24%. Postoperative AKI is a strong predictor of both short- and long-term cardiovascular mortality. The KDIGO criteria are used to better define and stage AKI. Pharmacological prevention strategies have shown limited effectiveness, prompting interest in ischemic preconditioning (IPC). Remote IPC has shown mixed results in cardiac and vascular surgery, depending on patient risk and protocols used. Local IPC, applied directly near the renal arteries, has shown promising renal protection in animal models. However, this technique has never been clinically tested in humans. We propose here a randomized trial to assess the efficacy of local IPC before suprarenal aortic clamping during open repair of juxta-renal AAA to reduce postoperative AKI.",[25],"NOT_YET_RECRUITING","2026-06-05",{"date":62,"type":35},"2026-06-09",{"date":64,"type":20},"2026-09-01",{"date":66,"type":20},"2029-12-01",{"name":68,"class":42},"University Hospital, Rouen",7,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":43},"100627793","strength-tracking-from-wall-tichness-over-aortic-biomechanics-storm-100627793","NCT07453251","Strength Tracking From Wall Tichness Over Aortic Biomechanics (STORM)","Strength Tracking From Wall Tichness Over Aortic Biomechanics","STORM","Inclusion Criteria:\n\n* Patients undergoing cardiac surgery for either aortic root and\u002For ascending aortic aneurysms; • Patients that have received, understood and signed the written informed consent for this study.\n\nExclusion Criteria:\n\n* Patients that have already undergone previous cardiac surgery; • Patients that present with acute aortic pathologies, such as acute aortic dissection or intramural hematoma.",{"count":79,"type":20},40,"The aim of the study is to analyse the resected portion of aneurysmatic ascending aorta in order to assess its strength to rupture, standardise the various measurements performed within the lab and try to correlate these qualitative results with quantitative results (regarding aortic diameter, valve morphology and aortic wall thickness).",[25,82],"Aneurysm Aortic Root",[84,85,86,87,88,89],"aortic aneurysm","bicuspid aortic valve","tricuspid aortic valve","tensile testing","aortic strength","aortic rupture","2026-03-09",{"date":92,"type":35},"2026-03-11",{"date":94,"type":35},"2025-10-25",{"date":96,"type":20},"2026-12",{"name":41,"class":42},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":54,"phases":107,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":5},"100476082","evaluation-of-the-valiant-captivia-physician-fenestrated-stent-graft-system-in-aortic-arch-and-descending-thoracic-aorta-pathologies-100476082","NCT05479305","Evaluation of the Valiant Captivia Physician Fenestrated Stent Graft System in Aortic Arch and Descending Thoracic Aorta Pathologies","EVERGREEN","Inclusion Criteria:\n\nTAA\u002FPAU (Thoracic Aortic Aneurysms and Penetrating Ulcers):\n\n1. Subject is at least 18 years of age.\n2. Subject understands and has signed an Informed Consent approved by the Sponsor for this study.\n3. Subject must be considered a candidate for revascularisation of BT, LCCA and LSA.\n4. Subject must be able to tolerate surgical revascularisation of BT, LCCA and LSA.\n5. Subject has a TAA\u002FPAU which is:\n\n   * a fusiform aneurysm with a diameter of ≥ 5.5 cm OR is \\> 2 times the diameter of the non-aneurysmal thoracic aorta; AND\u002FOR\n   * a saccular aneurysm or PAU (ulcer defined as ≥ 10 mm in depth and 20 mm in diameter, or symptomatic)\n6. Subject has a healthy, non-diseased aortic proximal seal zone of at least 20 mm\n7. Subject has no thrombus in the proximal neck\n8. Subject has a non-diseased aortic diameter between 25 mm and 42 mm and max diameter of the ascending aorta is ≤ 40 mm\n9. Subject has a non-diseased LSA which is eligible for stent-grafting\n10. Subject has sufficient landing zone within the LSA to accommodate the stent-graft without occlusion of any significant vessels\n11. Brachial, iliac or femoral artery access vessel morphology (diameter, calcification, tortuosity) that is compatible with vascular access techniques, the device, or accessories.\n12. Symptomatic patient who needs semi urgent repair; aptient is at high surgical risk and cannot wait for 6-8 weeks for a custom-made stent graft\n13. Subject is affiliated with the social security system\n\nInclusion criteria:\n\nTBAD(Type B Dissections) and Residual dissection after Type A repair:\n\n1. Subject is at least 18 years of age.\n2. Subject understands and has signed an Informed Consent approved by the Sponsor for this study.\n3. a) Subject has a degenerative aortic arch aneurysm which will require coverage of the LSA and extension of the proximal seal zone to zone 0 And\u002For b) Subject has a complicated TBAD (acute, subacute or chronic) which will require coverage of the LSA and extension of the proximal seal zone to zone 0 And\u002For c) Subject has a complicated residual dissection after replacement of the ascending aorta for type A aortic dissection which will require coverage of the LSA and extension of the proximal seal zone to zone 0\n4. Subject has a healthy, non-diseased (without thrombus) aortic proximal seal zone of at least 20 mm\n5. Subject has a healthy, non-diseased (without thrombus) aortic distal seal zone of at least 20 mm\n6. Subject has a maximum diameter of the distal ascending aorta just above the BT of 40 mm\n7. Subject has a non-diseased aortic diameter between 28 mm to 42 mm and the ascending aorta ≤ 40 m\n8. Subject has a no atheromatous lesions int the arch and the BT, LCCA and LSA\n9. Brachial, iliac or femoral artery access vessel morphology (diameter, calcification, tortuosity) that is compatible with vascular access techniques, the device, or accessories\n10. Symptomatic patient who needs semi urgent repair; aptient is at high surgical risk and cannot wait for 6-8 weeks for a custom-made stent graft\n11. Subject is affiliated with the social security system\n\nExclusion Criteria:\n\n(Thoracic Aortic Aneurysms and Penetrating Ulcers, TAA\u002FPAU):\n\n1. Subject has an aneurysmal, tortuous, or atherosclerotic LSA.\n2. Subject has an aneurysmal, tortuous, or atherosclerotic LCCA.\n3. Subject has an aneurysmal, tortuous, or atherosclerotic BT.\n4. Subject has an ascending aorta diameter \\> 40 mm\n5. Subject has thrombus in the proximal neck\n6. Subject has an emergent need of treatment of the aortic pathology\n7. Subject has prohibitive calcification, occlusive disease, or tortuosity of intended sealing sites\n8. Subject has circumferential calcification in the common femoral or external iliac artery or in the common iliac artery with an intraluminal diameter (ID) less than 9 mm at any point proximal to or at the access vessel site unless a surgical adjunctive procedure is planned.\n9. Subject has an aortic atheroma classified as grade IV or grade V.\n10. Subject has had previous endovascular repair of the ascending\n11. Subject has significant and\u002For circumferential aortic mural thrombus at either the proximal or distal attachment sites that would compromise sealing of the device.\n12. Subject is pregnant\n13. Subject has a known allergy or intolerance to the device components.\n14. Subject is in acute renal failure\n15. Subject has a body habitus which prevents adequate visualisation of the aorta.\n16. Subject has coronary artery disease with unstable angina and who has not received treatment.\n17. Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration).\n18. Subject has active systemic infection and\u002For a mycotic aneurysm.\n19. Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observations of this study.\n20. Subject has other medical, social, or psychological problems that, in the opinion of the investigator, will interfere with treatment and follow-up procedures.\n21. Subject has a life expectancy of less than 2 years year.\n22. Subject requires treatment of an infrarenal aneurysm at the time of the implantation.\n23. Subject has had previous surgical or endovascular treatment of an infra-renal aortic aneurysm \\\u003C30 days of implantation of investigational device.\n24. Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion.\n25. Subject has had a cerebral vascular accident (CVA) within 3 months.\n26. Subject has had a myocardial infarction (MI) within 3 months.\n27. Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment\n\nExclusion criteria:\n\n(Type B Dissections, TBAD and residual dissection after Type A repair):\n\n1. Subject has an aneurysmal, tortuous, or atherosclerotic LCCA.\n2. Subject has an aneurysmal, tortuous, or atherosclerotic LSA.\n3. Subject has an aneurysmal, tortuous, or atherosclerotic BT.\n4. Subject has a dissected BT and or LCCA\n5. Subject has prohibitive calcification, occlusive disease, or tortuosity of intended sealing sites.\n6. Subject has circumferential calcification in the common femoral artery, external iliac artery or in the common iliac artery with an intraluminal diameter (ID) less than 9 mm at any point proximal to or at the access vessel site unless a surgical adjunctive procedure is planned.\n7. Subject has an aortic atheroma classified as grade IV or grade V.\n8. Subject has had previous endovascular repair of the ascending, arch\n9. Subject has significant and\u002For circumferential aortic mural thrombus at either the proximal or distal sealing sites that would compromise seal of the device\n10. Subject is pregnant\n11. Subject has a known allergy or intolerance to the device components\n12. Subject is in acute renal failure\n13. Subject has a body habitus which prevents adequate visualisation of the aorta.\n14. Subject has coronary artery disease with unstable angina and who has not received treatment.\n15. Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration).\n16. Subject has active systemic infection and\u002For a mycotic aneurysm.\n17. Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observationsof this study\n18. Subject has other medical, social, or psychological problems that, in the opinion of the investigator, will interfere with treatment and follow-up procedures.\n19. Subject has a life expectancy of less than 2 years.\n20. Subject requires treatment of an infrarenal aneurysm at the time of the implantation.\n21. Subject has had previous surgical or endovascular treatment of an infra-renal aortic aneurysm \\\u003C30 days of implantation of investigational device.\n22. Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion.\n23. Subject has had a cerebral vascular accident (CVA) within 3 months.\n24. Subject has had a myocardial infarction (MI) within 3 months.\n25. Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.\n\n    \\-",{"count":106,"type":20},30,[56],"The study objectives are to assess safety and effectiveness, measured acutely and at the 30-day visit after implantation of the Valiant Captivia physician fenestrated Stent Graft.\n\nClinical utility measures throughout the procedure and until discharge will be assessed",[110,25,111,112],"Penetrating Ulcer of Aorta","Type B Aortic Dissection","Residual Dissection After Type A Repair",[114,115,116],"aortic arch","descending thoracic aorta","valiant captivia stent graft","2024-04-30",{"date":119,"type":35},"2024-05-01",{"date":121,"type":35},"2023-11-21",{"date":123,"type":20},"2027-10",{"name":125,"class":126},"Ceric Sàrl","INDUSTRY"]